Icecure Medical Ltd ICCM
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
IceCure Highlights Clinical Data and Strong Physician Engagement for ProSense® Breast Cancer Cryoablation at EUSOBI 2026
-
IceCure Expands ProSense® ChoICE Study for Low-Risk Breast Cancer adding Legacy Health in Portland, OR as U.S. Clinical Site
-
IceCure Medical Receives Regulatory Approval to Market ProSense® in China
-
IceCure Signs Exclusive Distribution Agreement for ProSense® Cryoablation Systems in the Netherlands
-
West Cancer Center Receives IRB Approval to Commence IceCure's ChoICE Study for Breast Cancer Cryoablation
-
IceCure Highlights Two New Peer-Reviewed Publications Supporting Cryoablation in Breast Cancer Treatment De-Escalation
-
IceCure Reports its Financial Results for the First Half of 2026 with 45% Revenue Growth Year-Over-Year
-
IceCure Medical Adds Adventist Health as U.S. Clinical Site for its Post-Marketing "ChoICE" Study for Low-Risk Breast Cancer Cryoablation Treatment
Trading Information
- Previous Close Price
- $1.08
- Day Range
- $1.03–1.12
- 52-Week Range
- $1.03–26.97
- Bid/Ask
- $1.06 / $1.09
- Shares Outstanding
- 4.64M
- Market Cap
- $4.94M
- Volume/Avg
- 61,325 / 138,774
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.69
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Value
- Total Number of Employees
- 66
- Website
- https://www.icecure-medical.com
Valuation
|
Metric
|
ICCM
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.31 |
Price/Sales | 0.69 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ICCM
|
|---|---|
Quick Ratio | 2.44 |
Current Ratio | 2.87 |
Interest Coverage | −106.52 |
Quick Ratio
ICCM
Profitability
|
Metric
|
ICCM
|
|---|---|
Return on Assets (Normalized) | −110.49% |
Return on Equity (Normalized) | −187.24% |
Return on Invested Capital (Normalized) | −172.50% |
Return on Assets
ICCM
Medical Devices Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Abbott Laboratories
ABT
| LOCK|KZpGWsX | LOCK|DzhN | $176B | |||
| Medtronic PLC
MDT
| LOCK|yQj$LHC | LOCK|BsV& | $118B | |||
| Stryker Corp
SYK
| LOCK|l!&%@TW | LOCK|C!Q | $108B | |||
| Boston Scientific Corp
BSX
| LOCK|V!QsX@ | LOCK|m#py | $64B | |||
| Edwards Lifesciences Corp
EW
| LOCK|S^&N!L& | LOCK|%^>? | $50B | |||
| DexCom Inc
DXCM
| LOCK|F?fX%X%X | LOCK|^TV! | $32B | |||
| GE HealthCare Technologies Inc Common Stock
GEHC
| LOCK|H&Rg^j | LOCK|QW | $31B | |||
| Koninklijke Philips NV ADR
PHG
| LOCK|@@p | LOCK|J> | $24B | |||
| Steris PLC
STE
| LOCK|>$Z<!& | LOCK|N$^$p | $21B | |||
| Zimmer Biomet Holdings Inc
ZBH
| LOCK|!rjT^?j | LOCK|&Qz | $18B |
United States